Impedimed Limited · ASX:IPD

Impedimed — Non-Deal Roadshow (March 2009)

27 slides from Impedimed's roadshow presentation, Mar 30, 2009

  1. Slide 1: ASX Release - Investor Presentation

    ASX : IPD th 30 March 2009 For personal use only ASX RELEASE - INVESTOR PRESENTATION ImpediMed Limited wishes to advise that CEO Greg Brown is undertaking an investment roadshow visiting both Australian and US based institutional investors and will use the attached presentation to introduce the comp

  2. Slide 2: ImpediMed Limited: Surviving cancer without compromising lifestyle

    For personal use only ImpediMed Limited Surviving cancer without compromising lifestyle

  3. Slide 3: Safe Harbor: Forward Looking Statements

    Safe Harbor For personal use only Forward Looking Statements Certain sections of this presentation contain forward-looking statements which are based on management’s expectations, estimates, projections and assumptions. Words such as “expects,” “anticipates,” “plans,” “believes,” “scheduled,” “estim

  4. Slide 4: Overview

    Overview For personal use only  Commercial company with recent FDA cleared & launched point of care diagnostic device for lymphedema  Currently listed on the Australian Stock Exchange (fully diluted market k cap off ~US$40mm) S$ 0 )  Current shareholders include • Starfish Ventures • ORBIS • Macq

  5. Slide 5: Investment Highlights

    Investment Highlights For personal use only  Lymphedema y p represents p a large g & underserved market  Multi-hundred million dollar annual consumables market opportunity  ImpediMed p has the first cleared technology gy to enable pre-emptive p p care  Proven prevention of lymphedema progression

  6. Slide 6: What is Lymphedema?

    What is Lymphedema? For personal use only  Lymphatics y p - circulatoryy system y for immunityy & removal of cellular waste  Lymphedema - breakdown of the lymphatic's where transport capacity fails  Presently diagnosed when patients can already have irreversible changes  Painful lifelong conditi

  7. Slide 7: Lymphedema Incidence Rates

    Lymphedema Incidence Rates For personal use only Incidence of Lymphedema in Cancer Survivors • US breast cancer incidence – 240,000 cases/year • US Breast cancer survivors – 2.4 2 4 million • US pelvic cancer incidence – >450,000 cases/year • Women’s cancers, prostate, testicular, colon See referenc

  8. Slide 8: Our Solution - Early Detection, Early Intervention

    Our Solution -Early Detection, Early Intervention e e o For personal use only ImpediMed Ltd - Surviving Cancer Without Compromising Lifestyle

  9. Slide 9: Early Diagnosis and Treatment Results in Better Outcomes

    Early Diagnosis and Treatment Results in Better Outcomes For personal use only  5 year prospective NIH study  Conducted at National Naval Med Center  NIH and d Navy N IRB oversight i ht  Utilized a standardize metric for assessment of total arm volume not BIS • Breast cancer patients all pre-ope

  10. Slide 10: ImpediMed Enables the New Clinical Paradigm

    ImpediMed Enables the New Clinical Paradigm For personal use only High risk patient – homecare - therapist Surgeon Surgeon / L-Dex XCA baselines patient Oncologist |__|__|__|__|__|__|__|__|__|__|__| misc. code risk assessment $500 - $ $ $1000 Device misc. code consumables of $150-$300 per year Cance

  11. Slide 11: Positive Reimbursement Environment

    Positive Reimbursement Environment For personal use only  Women’s Health and Cancer Rights g Act of 1998 requires q coverage g of lymphedema care (HR 4328 Public Law 105-277)  Similar laws in 22 states  Patient Advocacy Foundation (PAF)  Providing reimbursement hotline support  Currently surgeo

  12. Slide 12: Positive Reimbursement Environment

    Positive Reimbursement Environment For personal use only  Requirements for category 1 code – technology specific BIS  Need an FDA clearance for a BIS device (completed)  Need to show it is billed on a miscellaneous code and that no other code is available (completed)  Need 5 years of US peer rev

  13. Slide 13: Bioimpedance Spectroscopy (BIS)

    Bioimpedance Spectroscopy (BIS) For personal use only BIS technology directly measures the extracellular fluid At low frequency At high frequency Cell membrane Intercellular fluid Extracellular fluid ImpediMed’s BIS Technique  10 years of peer reviewed science on earlier detection  Passes low-freq

  14. Slide 14: Lymphedema - Current Detection Methods and Limitations

    Lymphedema – Current Detection Methods and Limitations For personal use only Current detection methods Limitations May not detect until Tape measure lymphedema is irreversible Non-FDA approved Measures onlyy total volume change Archimedes method – water displacement j Subjective, non-standard me

  15. Slide 15: BIS is Superior to All Other Detection Methods

    BIS is Superior to All Other Detection Methods For personal use only Assessment ss ss and d Monitoring o o g Tools oo s Symptom Bioimpedance Archimedes Tape measure Perometer assessment Sensitivity Specificity Quantification Ease of use Time to measure Portability Evidence based YES NO YES YES YES 

  16. Slide 16: Commercial & Regulatory Status

    Commercial & Regulatory Status For personal use only L-Dex U400  Single channel BIS device  FDA cleared October 2008  Clinical assessment for uni- lateral lymphedema of the arm  Uni-Leg submission mid CY2009  Over 10 yyears of p peer reviewed science built on BIS L-Dex UB500  Multiple channel

  17. Slide 17: Business Model

    Business Model For personal use only L-Dex U400  Place L-Dex devices in surgeons office free of charge  Price per test of US$25 - $45  If a surgeon enrolls 8 new patients per month and is testing patients quarterly over the first two years, the placement will build to a monthly test volume of 64

  18. Slide 18: Intellectual Property

    Intellectual Property For personal use only  Strong Patent Portfolio  12 patent families  Filed internationallyy  Covers BIS technology and consumable approach  Key Trademarks  Key brands and initiatives trademarked  L-Dex  Know your LL-Dex Dex ImpediMed Ltd - Surviving Cancer Without Compro

  19. Slide 19: Focused Launch Strategy

    Focused Launch Strategy For personal use only  Physicians – initially targeting 5000 specialist breast surgeons  Building the sales force from 4 reps to 40 reps  Increase technical/training staff  ASBS sponsored d registry  Patients  Enrollment p program g – all breast cancer p patients offere

  20. Slide 20: ImpediMed's Technology Benefits all Parties

    ImpediMed’s p Technology gy Benefits all Parties For personal use only  Physicians – haven haven’tt had a realistic option previously – now have a reliable, easy to use predictive tool; profitable for their practices  Patients – common fear given incidence/unsightliness, ability to have some contr

  21. Slide 21: Operations

    Operations For personal use only  US facilities f iliti - San S Di Diego US operations/headquarters ti /h d t  15 employees  7 employees presently in sales, marketing  Australian facilities- Brisbane  10 employees (R&D, accounts, ROW S&M etc.)  M Manufacturing f t i willill be b split lit betw

  22. Slide 22: Recent Financials

    Recent Financials For personal use only As reported in Australian Dollars ($000) $K AU 2H 2008 USD (0.65) Revenue 1567 1 018 1,018 Profit from continuing opns (7,750) (5,037) EBITDA (7,417) (4,821) Current assets 7,685 4,995 Current liabilities (2,151) (1,398) Debt 0 0 •Average US$ exchange 0.909:1

  23. Slide 23: Ownership Profile

    Ownership Profile For personal use only % of Ownership p Public Funds ORBIS 14.8% Macquarie 6.1% Other institutional investors 9 0% 9.0% Venture Capital Starfish Ventures 26.9% Versant Ventures 5.7% Management 10.1% Shares outstanding 90.2m, options outstanding 17.9m WAEP 78 cents ImpediMed Ltd - Su

  24. Slide 24: Investment Highlights

    Investment Highlights For personal use only  Lymphedema y p represents p a large g & underserved market  Multi-hundred million dollar annual consumables market opportunity  ImpediMed p has the first cleared technology gy to enable pre-emptive p p care  Proven prevention of lymphedema progression

  25. Slide 25: Thank you

    For personal use only ImpediMed Thank you ImpediMed, Inc: 858.412.0200 info@impedimed.com www.impedimed.com www.L-Dex.com ASX:IPD ImpediMed Ltd - Surviving Cancer Without Compromising Lifestyle

  26. Slide 26: Reference Information

    Reference Information For personal use only 1. Warren A, Brorson H, Borud L, and Slavin S, Lymphedema: A Comprehensive Review, Annals of Plastic Surgery • Volume 59, Number 4, 2007 2. Francis 2 F i WP, WP AbAbghari h i P, P Du D W, W Rymal R l C, C Suna S M, M Kosir K i MA. MA Improving I i surgical

  27. Slide 27: Reference Information (Cont)

    Reference Information (Cont) For personal use only 11. Armer JM, Stewart BR. A comparison of four diagnostic criteria for lymphedema in a post-breast cancer population. Lymphat Res Biol 2005;3(4):208-17. ; ( ) Available from http://www.ncbi..nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=

ImpediMed — Non-Deal Roadshow (March 2009) on 6ix